Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
2022
Abstract
Venetoclax is an effective therapy for chronic lymphocytic leukemia (CLL) with the potential to induce deep remissions.1-5 Furthermore, venetoclax in combination with an anti-CD20 antibody is now approved on fixed-duration treatment schedules (front-line: 12 months with obinutuzumab3 ; relapsed/refractory: 24 months with rituximab).2 As fixed-duration venetoclax-based therapies are increasingly used, more patients will require CLL therapy after venetoclax.